Bardoxolone methyl: drug development for diabetic kidney disease | SpringerLink
Can Activation of NRF2 Be a Strategy against COVID-19?: Trends in Pharmacological Sciences
The chemical structure of bardoxolone methyl. | Download Scientific Diagram
Bardoxolone methyl - Wikipedia
Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease | Signal Transduction and Targeted Therapy
Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure | Journal of Pharmacology and Experimental Therapeutics
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease - ScienceDirect
Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney | American Society of Nephrology
Bardoxolone conjugation enables targeted protein degradation of BRD4 | Scientific Reports
Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Imp
Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites | Journal of Medicinal Chemistry
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes | NEJM
Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells | Molecular Pharmacology
Pharmacodynamics of bardoxolone methyl. A, levels of NF- k B, cyclin... | Download Scientific Diagram